Evemesa
Generic Name
Mesalazine (Mesalamine)
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| evemesa 2 gm microgranules | ৳ 90.00 | N/A |
Description
Overview of the medicine
Evemesa 2 gm microgranules contain mesalazine, an anti-inflammatory drug used to treat and prevent flare-ups of inflammatory bowel diseases like ulcerative colitis and Crohn's disease. It works by reducing inflammation in the colon and rectum.
Uses & Indications
Dosage
Adults
For ulcerative colitis: Typically 2-4 gm once daily or in divided doses. Dosage may vary based on disease activity and formulation.
Elderly
Use with caution; dose adjustment may be necessary due to potential for decreased renal function.
Renal_impairment
Caution advised; avoid in severe renal impairment. Dose reduction may be required.
How to Take
Oral administration. The microgranules can be taken with or without food. They should be poured onto the tongue and swallowed whole with water or mixed with yogurt or apple sauce, immediately consuming the mixture. Do not chew or crush the microgranules.
Mechanism of Action
Mesalazine is a 5-aminosalicylate (5-ASA) that acts locally in the bowel. Its exact mechanism is not fully understood but is thought to involve inhibition of prostaglandin and leukotriene synthesis, scavenging free radicals, and modulation of immune responses, thereby reducing inflammation in the gastrointestinal tract.
Pharmacokinetics
Onset
Symptom improvement typically within 2-4 weeks.
Excretion
Mainly via feces (unabsorbed drug) and urine (metabolite).
Half life
Parent compound: 0.5-1.5 hours; N-acetylmesalazine (metabolite): 5-10 hours.
Absorption
Minimal systemic absorption; primarily acts locally in the colon. Absorption varies with formulation.
Metabolism
Primarily acetylated in the intestinal wall and liver to N-acetylmesalazine, which is pharmacologically inactive.
Side Effects
Contraindications
- Hypersensitivity to mesalazine or salicylates
- Severe renal or hepatic impairment
- Gastric or duodenal ulcer
Drug Interactions
NSAIDs
May increase the risk of nephrotoxicity.
Azathioprine, 6-mercaptopurine, thioguanine
Increased risk of myelosuppression.
Storage
Store below 30°C in a dry place, away from direct sunlight and moisture. Keep out of reach of children.
Overdose
Symptoms: Nausea, vomiting, abdominal pain, drowsiness, dizziness, headache. Management: Symptomatic and supportive care. Gastric lavage or activated charcoal may be considered if recent ingestion. Monitor renal and hepatic function.
Pregnancy & Lactation
Use during pregnancy only if clearly needed and potential benefits outweigh risks. Mesalazine crosses the placenta. Excreted in breast milk, use with caution during lactation; monitor infant for diarrhea.
Side Effects
Contraindications
- Hypersensitivity to mesalazine or salicylates
- Severe renal or hepatic impairment
- Gastric or duodenal ulcer
Drug Interactions
NSAIDs
May increase the risk of nephrotoxicity.
Azathioprine, 6-mercaptopurine, thioguanine
Increased risk of myelosuppression.
Storage
Store below 30°C in a dry place, away from direct sunlight and moisture. Keep out of reach of children.
Overdose
Symptoms: Nausea, vomiting, abdominal pain, drowsiness, dizziness, headache. Management: Symptomatic and supportive care. Gastric lavage or activated charcoal may be considered if recent ingestion. Monitor renal and hepatic function.
Pregnancy & Lactation
Use during pregnancy only if clearly needed and potential benefits outweigh risks. Mesalazine crosses the placenta. Excreted in breast milk, use with caution during lactation; monitor infant for diarrhea.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24-36 months from manufacturing date
Availability
Pharmacies, hospitals
Approval Status
Approved by major regulatory bodies (e.g., FDA, EMA, DGDA for Bangladesh)
Patent Status
Generic available, original patent expired
WHO Essential Medicine
YesClinical Trials
Extensive clinical trials support the efficacy and safety of mesalazine in ulcerative colitis and Crohn's disease. Specific trials for this microgranule formulation demonstrate its targeted drug delivery.
Lab Monitoring
- Renal function tests (creatinine, BUN) at baseline, regularly during treatment (e.g., quarterly for the first year, then annually)
- Liver function tests (ALT, AST) periodically
- Complete blood count (CBC) periodically
Doctor Notes
- Emphasize patient compliance, especially with the non-chewing/crushing instruction for microgranules.
- Monitor renal function regularly.
- Advise patients to report any new or worsening symptoms promptly.
Patient Guidelines
- Take as directed by your doctor, do not chew or crush the microgranules.
- Report any unusual symptoms like severe abdominal pain, chest pain, or changes in urine output.
- Maintain adequate hydration.
Missed Dose Advice
If a dose is missed, take it as soon as you remember, unless it is almost time for your next dose. In that case, skip the missed dose and resume your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
Generally no effect on driving or operating machinery. However, if you experience dizziness or fatigue, avoid these activities.
Lifestyle Advice
- Maintain a healthy diet to support gut health.
- Avoid known triggers for IBD flare-ups.
- Manage stress effectively.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Evemesa Brand
Other medicines available under the same brand name
